Grifols (NASDAQ:GRFS) Sees Strong Trading Volume – Should You Buy?

Grifols, S.A. (NASDAQ:GRFS) shares saw strong trading volume on Wednesday . 1,121,503 shares traded hands during mid-day trading, an increase of 65% from the previous session’s volume of 679,574 shares.The stock last traded at $8.2210 and had previously closed at $8.00.

Analyst Upgrades and Downgrades

GRFS has been the subject of several analyst reports. Wall Street Zen cut Grifols from a “buy” rating to a “hold” rating in a report on Monday, May 18th. Zacks Research upgraded shares of Grifols from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Finally, Weiss Ratings downgraded shares of Grifols from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. Three equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Grifols currently has a consensus rating of “Reduce” and an average price target of $10.00.

Grifols Trading Up 1.9%

The business’s 50-day simple moving average is $7.51 and its two-hundred day simple moving average is $8.19. The firm has a market capitalization of $5.55 billion, a price-to-earnings ratio of 43.05, a PEG ratio of 0.30 and a beta of 0.67. The company has a quick ratio of 0.85, a current ratio of 2.47 and a debt-to-equity ratio of 1.16.

Grifols Announces Dividend

The firm also recently disclosed a special dividend, which was paid on Thursday, July 9th. Investors of record on Thursday, July 2nd were issued a $0.0945 dividend. The ex-dividend date was Thursday, July 2nd. Grifols’s payout ratio is 121.05%.

Institutional Trading of Grifols

A number of large investors have recently made changes to their positions in the company. Allworth Financial LP increased its position in Grifols by 15.7% during the fourth quarter. Allworth Financial LP now owns 8,073 shares of the biotechnology company’s stock worth $75,000 after buying an additional 1,096 shares during the period. Cerity Partners LLC increased its stake in Grifols by 6.3% in the fourth quarter. Cerity Partners LLC now owns 19,121 shares of the biotechnology company’s stock valued at $179,000 after purchasing an additional 1,131 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Grifols by 25.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,928 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 1,212 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Grifols by 10.1% during the first quarter. Bank of New York Mellon Corp now owns 16,419 shares of the biotechnology company’s stock worth $132,000 after buying an additional 1,511 shares during the last quarter. Finally, Versant Capital Management Inc increased its position in Grifols by 36.0% in the 2nd quarter. Versant Capital Management Inc now owns 6,958 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 1,842 shares during the period.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.